Latest news about Phaarmasia
Phaarmasia
83.50
+0.03(+0.04%)
Company Performance:
View Company Insights1D+0.04%
1M-14.93%
6M+9.72%
1Y+209.26%
5Y+143.80%
More news about Phaarmasia
13Oct 25
Phaarmasia Limited Board Approves Sale of Hyderabad Property Following Shareholder Consent
Phaarmasia Limited's Board of Directors has approved the sale of land and building in Hyderabad's IDA Jeedimetla area following shareholder approval via postal ballot. The resolution passed with 99.23% votes in favor. The board authorized specific executives to execute the sale agreement and register the sale deed. This decision could significantly impact the company's financial structure and future operations in the pharmaceutical sector.
13Sept 25
Phaarmasia Limited Seeks Shareholder Approval for ₹25 Crore Property Sale
Phaarmasia Limited has initiated a postal ballot to gain shareholder approval for selling its land and building in Hyderabad for a minimum of ₹25 crores. The property, located at IDA Jeedimetla, is to be sold to Mr. Mavuluri Shyam Prasad, Mrs. Mavuluri Raga Sudha, and/or MSP LAB INSTRUMENTS PRIVATE LIMITED. The sale aims to optimize the company's asset portfolio and strengthen its financial position. E-voting for shareholders will run from September 13 to October 12, 2025. The Board of Directors recommends approval of this special resolution, with the transaction expected to complete by December 31, 2025.
13Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Up 26.6% QoQ, Net Profit Rebounds
Phaarmasia Limited announced Q1 FY2026 results with revenue from operations at Rs 687.36 lakhs, up 26.6% QoQ. The company reported a net profit of Rs 27.02 lakhs, compared to a loss in the previous quarter. Total income reached Rs 718.88 lakhs, with total expenses at Rs 687.58 lakhs. EPS for the quarter was Rs 0.40. The company maintained its paid-up equity share capital at Rs 682.70 lakhs and reported zero outstanding loans or debt securities.
11Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Declines 17.1% YoY, Shows Sequential Improvement
Phaarmasia Limited's Q1 FY2026 results show a 17.1% year-over-year revenue decline to Rs. 687.36 lakhs, but a 26.6% sequential increase from Q4 FY2025. Net profit marginally decreased by 2.2% YoY to Rs. 27.02 lakhs. The company returned to profitability after a loss in the previous quarter. Total expenses decreased by 16.1% YoY, helping to mitigate the impact of lower revenue. EPS remained stable at Rs. 0.40.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,782.20
(+0.12%)
6,623.00
(+0.40%)
4,420.90
(+1.87%)
1,401.30
(+0.19%)
1,089.00
(+0.41%)
1,278.20
(+0.84%)
2,267.70
(+0.80%)
2,336.10
(-0.72%)
1,462.30
(-0.09%)
1,446.80
(+1.37%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
